Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study

Infliximab and vedolizumab are effective treatments for inflammatory bowel disease (IBD), although associated with adverse events (AE). While low or non-existent drug levels and positive antidrug antibodies have been associated with therapeutic failure, there is no clear association between higher d...

Full description

Bibliographic Details
Main Authors: Ido Veisman, Oranit Barzilay, Liora Bruckmayer, Ola Haj-Natour, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin, Bella Ungar
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Clinical Medicine
Subjects:
IBD
infliximab
vedolizumab
biological therapy
Online Access:https://www.mdpi.com/2077-0383/10/18/4265

Internet

https://www.mdpi.com/2077-0383/10/18/4265

Similar Items